Three innovative studies at AACR IO 2026 presented new ways for CAR T cells and antibody-lectin chimeras to tackle...
In the past couple of decades, progress against cancer has created a new generation of survivors. Today, more than...
About 80 percent of lung cancers are non-small cell lung cancers (NSCLC), and about 15 to 20 percent of...
The AACR-Bayer Innovation and Discovery Grants program supports researchers who are seeking to develop new treatment options for cancers...
Although checkpoint inhibitors and other immunotherapies are remarkably effective for patients with some cancers, demonstrating durable antitumor activity and/or...
“Do you want to have fun?” Richard Pazdur, MD, director of the U.S. Food and Drug Administration (FDA) Oncology...
Immune checkpoint inhibitors have become part of the standard of care for more than 14 different cancer types, including...
Persistent infections from pathogens are a major cause of cancer incidence worldwide. An analysis from 2012 indicates that more...
Cancer immunotherapy research has exploded in recent years. This treatment utilizes a patient’s own immune system to recognize and...
A pair of studies presented at the AACR Annual Meeting 2019 demonstrated encouraging clinical outcomes with two different chimeric...
Recent advances in cancer research has led to enormous progress against many cancer types. From 1991 to 2015, we...